Connective Tissue Supplementation
A breakdown of connective tissue is common amongst many patients experiencing joint pain and mobility issues. Often, this breakdown in connective tissue is addressed with opiates or steroids to ease the patient’s discomfort.
When we experience pain, our body is sending us a message that something is wrong. Pain is merely a symptom of an underlying condition or injury. Using steroids or opiates alone to address pain caused by injury is akin to putting a picture over a hole in the wall instead of repairing the hole.
With connective tissue supplementation, you have an opportunity to address the problem at its source by inserting new, viable connective tissue (ECM) directly to the site of the breakdown, or defect (via syringe). The patient’s body can use the collagenic superstructure from the newly transplanted Wharton’s jelly as building blocks to fill voids or defects in cartilage beds or other soft tissues.
Effectively, you can identify & address the root cause instead of treating symptoms, giving your patients a shot at long-term improvement in their quality of life.
How do Wharton’s Jelly Allografts work?
Umbilical cord tissue is shown to be structurally similar to articular cartilage and other soft tissues throughout the body. There are many components of WJ that are beneficial for transplantation. The most prominent of these components is the ECM (extracellular matrix), a collagen-based, cross-linked network that adds tensile strength and distributes load, making it an excellent choice for patients with musculoskeletal injuries.
Wharton’s jelly (WJ) allografts consist of human umbilical cord tissue that has been disassociated, suspended in saline, and cryopreserved. Their main function is to replace missing or damaged tissue in the patient, applied directly to the defect, or injured area, in soft tissues. They are applied via syringe and are typically used in ligament, muscle, or cartilage tears.
About Regenative Labs
Regenative Lab’s mission is to facilitate predictable patient outcomes by providing the highest quality human tissue allografts available. With the goal of addressing the root cause, rather than masking the pain, Regenative Labs birth tissue allografts provide a non-addictive, minimally invasive option for patients. Regenative Labs products are manufactured in state-of-the-art ISO certified cleanrooms. All equipment is calibrated and validated to ensure valid and consistent results are produced.
How is Wharton’s jelly administered?
Wharton’s jelly is administered via syringe, with real time visualization utilizing ultrasound guidance, directly to the injured site, or defect. The application is relatively painless and takes mere minutes.
How many applications do I need?
This is determined by Dr. Parker depending on your specific case, but multiple applications may be required to reach the desired clinical outcome.
Is Wharton’s jelly application safe?
Yes! There have been no known graft vs. host interactions nor drug interactions with our product. It is well established that these products are safe. Dr. Parker will determine if this product has any contraindications during your examination such as pregnancy, active cancer, etc. To date, no adverse events have been reported contributable to Regenative Labs’ products in over 50,000 applications.
What should I do post-application?
This is up to your Dr. Parker’s discretion, however it is usually a good idea to take it easy for the first 24-48 hours, but beyond that, there is typically little change in daily activities post-application. WJ application takes only minutes & is non-allogeneic, nonsurgical, and minimally invasive. Patients walk in and walk back out the same day; however, they will need to take it easy for the first 24-48 hours, eliminate high impact activities for the first 2 to 4 weeks, and avoid using NSAIDs such as Motrin, Advil, Aleve, etc.
What do Wharton’s jelly Allografts help with?
Wharton’s jelly allografts are connective tissue supplements designed to replace missing or damaged tissue in the patient. If missing or damaged tissue is identified after imaging, you may be a candidate for Wharton’s jelly application.
About Wharton’s Jelly
Regenative Labs Wharton’s jelly allografts are regulated under section 361 of the Public Health Service Act (PHS) and 21 CFR Part 1271. ProText™ is processed to preserve the structural integrity and original relevant characteristics of Wharton’s jelly as observed in the donor and is intended for homologous use only. Regenative Labs’ products are ethically derived and do not contain any material obtained from an embryo or fetus. Regenative Labs birth tissue allografts are derived from healthy, consenting mothers after full-term, live, planned, Cesarean section (C-section) deliveries.
Advantages Of Wharton’s Jelly
This connective tissue contains high amounts of extracellular matrix components including collagen types I, III, and V, elastin, and fibronectin that provide a natural scaffold to facilitate cellular adhesion. Wharton’s jelly primarily provides cushioning and structural support to the umbilical cord but also contains a natural source of long-chain hyaluronic acid as well as numerous cytokines and growth factors. Studies have described placental tissues to be “immune privileged” as they rarely evoke an immune response in the body, reducing the risk of adverse reaction.
How do I know if Wharton’s jelly is right for me?
If you are suffering from pain, you may have an underlying structural tissue defect that is the root cause. Instead of treating your symptoms (pain) with steroids or other conventional methods, Wharton’s jelly addresses the root cause by fixing your “tissue issue.”
Schedule an appointment with Dr. Parker at the bottom of this page to see if you qualify for Wharton’s Jelly application.
“Pain Week” Medical Conference
Recently, Dr. Parker gave a presentation on Achilles Tendon Repair, while also attending Pain Week in Las Vegas to constantly further his knowledge and stay up to date with the newest research and development in the medical industry.
The conference had over 2000 attendees and he was one of 5 doctors asked to speak on his poster-presentation, one of 80 posters total.